PRISM®
Search documents
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
Globenewswire· 2025-11-04 13:30
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Monday, November 10, 2025, to review the company’s third quarter 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave ...
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
Globenewswire· 2025-09-18 12:30
Core Insights - Wave Life Sciences Ltd. is hosting a virtual Research Day on October 29, 2025, at 10:00 a.m. ET to discuss its advancements in RNA medicines [1][3] - The company will also participate in several investor conferences, including the Bernstein 2nd Annual Healthcare Forum and the Stifel Virtual Cardiometabolic Forum [2] Company Overview - Wave Life Sciences is a biotechnology company focused on RNA medicines, utilizing its PRISM® platform to address both rare and common disorders [4] - The company's RNA-targeting modalities include editing, splicing, RNA interference, and antisense silencing, which enhance its capabilities in developing therapeutic candidates [4] - Wave's pipeline includes clinical programs targeting alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs [4]
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025
Globenewswire· 2025-07-23 12:30
Core Viewpoint - Wave Life Sciences Ltd. is set to host a live webcast and conference call on July 30, 2025, to discuss its second quarter 2025 financial results and provide business updates [1]. Company Overview - Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health [3]. - The company's RNA medicines platform, PRISM®, integrates various modalities and chemistry innovations to address both rare and common disorders [3]. - Wave's pipeline includes clinical programs targeting Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity, along with several preclinical programs [3]. - The company is headquartered in Cambridge, MA, and emphasizes its mission to "Reimagine Possible" in the context of human health [3]. Event Details - The webcast and conference call will be accessible via the "Investor Events" section on the Wave Life Sciences website [2]. - An archived version of the webcast will be available after the live event [2].
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
Globenewswire· 2025-05-01 12:30
Company Overview - Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on RNA medicines to transform human health [3] - The company utilizes its RNA medicines platform, PRISM®, which integrates various modalities and chemistry innovations to address both rare and common disorders [3] - Wave's pipeline includes clinical programs targeting Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity, along with several preclinical programs [3] Upcoming Events - Wave Life Sciences will host a live webcast and conference call on May 8, 2025, at 8:30 a.m. ET to review Q1 2025 financial results and provide business updates [1] - The event can be accessed via the "Investor Events" section on the company's website [2] - An archived version of the webcast will be available on the company's website following the live event [2]